论文部分内容阅读
二肽基肽酶(DPP-Ⅳ)抑制剂是治疗Ⅱ型糖尿病的新药,因其无低血糖、体重增加以及胃肠道相关问题而备受青睐。本文综述DPP-Ⅳ抑制剂上市品种的市场表现及后续品种的开发。
Dipeptidyl peptidase (DPP-IV) inhibitors are new drugs for the treatment of type 2 diabetes and are favored for their lack of hypoglycaemia, weight gain and gastrointestinal problems. This article reviews the market performance of DPP-IV inhibitors listed and the development of subsequent varieties.